Anticoagulant Market Spoiled By Choice? Cost May Be True Differentiator
A new Lancet meta-analysis suggests that while four new anticoagulants are more effective than warfarin, there is little differentiation among the products. Pressed to compare the drugs at AHA, experts were apt to highlight similarities and call for competitive pricing and head-to-head trials.
You may also be interested in...
A wave of data to support use of novel anticoagulants in real-world settings was presented at the European Society of Cardiology Congress, but the question is whether this will alter the course of the market still dominated by warfarin and trailed by J&J/Bayer's Xarelto.
Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.
Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation and at risk of stroke. Results are due in 2020.